By targeting the upstream determinants of mesenchymal expression, such as TGF-β and FOXL1 or by targeting the downstream drivers of BMP signaling such as GREM1 and ISLR, one may identify new approaches to prevent and treat cancer. The gene discussed is FOXL1; the disease is cancer.